

Original Paper

Effectiveness of the Mobile-Based Diabetes Little Helper Video Intervention on Medication Adherence Among Older Adults Living With Type 2 Diabetes Mellitus, Henan, China: Randomized Controlled Trial

Meng Wang¹, PhD; Khuan Lee¹, PhD; Hui Zhu Thew², MMed; Siti Noorkhairina Sowtali³, PhD; Qiuhan Jiang⁴, MPH; Zhengyan Zhao⁵, BSN; Yu Liu⁶, MNS; Poh Ying Lim⁷, PhD

¹Department of Nursing, Faculty of Medicine & Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia

²Department of Family Medicine, Faculty of Medicine & Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia

³Department of Professional Nursing Studies, Kulliyyah of Nursing, International Islamic University Malaysia, Pahang, Malaysia

⁴Henan Provincial People's Hospital, Zhengzhou, China

⁵Zhengzhou Seventh People's Hospital, Zhengzhou, China

⁶The Second Mobile Contingent Hospital of the Chinese People's Armed Police Forces, Wuxi, China

⁷Department of Community Health, Faculty of Medicine & Health Sciences, Universiti Putra Malaysia, Serdang, Malaysia

Corresponding Author:

Poh Ying Lim, PhD

Department of Community Health, Faculty of Medicine & Health Sciences

Universiti Putra Malaysia

Jalan Universiti 1

Selangor, Serdang, 43400

Malaysia

Phone: 60 397692950

Email: pohying_my@upm.edu.my

Abstract

Background: Medication adherence is vital for older adults living with type 2 diabetes mellitus (T2DM), but it remains low and needs improvement. Current interventions have limited effectiveness, while video-based interventions show promising potential for enhancing adherence.

Objective: To evaluate the impact of the “Diabetes Little Helper” video intervention, developed based on the information–motivation–behavioral skills model, on improving medication adherence in older adults living with T2DM in Henan.

Methods: This parallel-group randomized controlled trial was conducted in 2 hospitals in Zhengzhou, involving 68 patients from each hospital. The intervention group (IG) received standard care plus the video intervention for one month, while the control group (CG) received only standard care. The primary outcome was medication adherence, and secondary outcomes included medication knowledge, attitude, behavior, belief, and social support. Data were collected at baseline, postintervention, and at 3-month follow-up. Intention-to-treat analysis and the last observation carried forward method were applied for missing data, with the generalized estimating equation model used for effect assessment ($P<.05$ considered statistically significant).

Results: The average age of participants in the IG was 67.5 (SD 8.0) years, while in the CG, the average age was 66.0 (SD 7.0) years. Sex distribution was nearly identical, with 51.5% (n=35) of participants in the IG and 50.0% (n=34) in the CG being male. After the intervention, the IG and CG had retention rates of 95.6% (n=65) and 97.1% (n=66), respectively. At the 3-month follow-up, the retention rates for the IG and CG were 92.6% (n=63) and 92.2% (n=62), respectively. Both postintervention ($\beta=4.956$, 95% CI 3.702-6.210, $P<.001$) and at the 3-month follow-up ($\beta=3.691$, 95% CI 2.379-5.003, $P<.001$), medication adherence score for the IG was significantly higher than that for the CG. In addition, the IG showed significant improvements in secondary outcome, with medication knowledge ($\beta=11.592$, 95% CI 6.923-16.260, $P<.001$), attitude ($\beta=5.467$, 95% CI 4.531-6.763, $P<.001$), behavior ($\beta=4.176$, 95% CI 3.220-5.133, $P<.001$), and belief ($\beta=2.882$, 95% CI 1.990-3.775, $P<.001$) compared with the CG postintervention. However, there was no statistically significant difference in the secondary outcome of social support ($\beta=0.008$, 95% CI -1.834 to 2.011, $P=.928$).

Conclusions: The Diabetes Little Helper video intervention effectively improved medication adherence in older adults living with T2DM in Henan, highlighting the potential of digital health tools for managing chronic diseases in older adult populations.

Trial Registration: Chinese Clinical Trial Registry ChiCTR2400083282; <https://www.chictr.org.cn/showprojEN.html?proj=214847>

(*J Med Internet Res* 2026;28:e78731) doi: [10.2196/78731](https://doi.org/10.2196/78731)

KEYWORDS

older adults; video; type 2 diabetes mellitus; medication adherence; randomized controlled trial

Introduction

With the continuous improvement of economic levels, changes in lifestyle, and the accelerated process of population aging, the prevalence of diabetes mellitus (DM) has been steadily increasing, becoming a significant global public health challenge [1,2]. In 2021, the number of people aged 20-79 years with DM worldwide was approximately 536.6 million, and it is projected to rise to 783.2 million by 2045 [3]. The older adults, due to factors such as physiological decline, metabolic imbalance, and the coexistence of chronic diseases, represent a high-risk group for DM. In 2019, the number of people aged 65 years and older with DM worldwide reached 135.6 million, and it is expected to increase to 276.2 million by 2045 [4].

As one of the countries with the highest burden of DM, the trend of DM prevalence in China is consistent with the global pattern. The number of people aged 20-79 years with DM in China increased from 88.7 million in 2020 to over 108.4 million [5]. Among these, type 2 diabetes mellitus (T2DM) is the predominant form, accounting for 90%-95% of all DM cases, with the older adults being the primary affected group [6-9]. T2DM significantly shortens the lifespan of patients and can lead to severe complications, including cardiovascular diseases, kidney disease, retinopathy, and neuropathy, potentially resulting in organ failure [10-15]. Due to the long duration of the disease and the presence of multiple complications, older adults living with T2DM are at higher risk of developing complications such as diabetic foot, stroke, and nephropathy [16,17]. Medication treatment is crucial in the management of T2DM, and its effectiveness is highly dependent on patient adherence to medication, that is, whether patients follow the prescribed treatment regimen consistently [18,19]. Studies have shown that patients with high medication adherence not only experience more stable disease control but also significantly reduce mortality, hospitalization rates, and health care costs [20-22]. However, in China, more than half of older adults living with T2DM experience poor medication adherence [23,24], which severely limits the long-term effectiveness of DM management and urgently calls for effective intervention strategies. Research indicates that various factors contribute to poor medication adherence, including age [25], economic burden [26], and multiple medications [27]. To improve medication adherence among older adults, various intervention strategies have been attempted both domestically and internationally, including health management based on multidisciplinary collaborative models [28], face-to-face health education [29], mobile app support [30], and motivational interviewing [31]. However, these approaches generally face challenges such as high

implementation costs, complex operations, and a strong reliance on health care resources. Furthermore, most lack systematic theoretical models, making them difficult to adapt to older adults with lower educational levels [32,33]. The information-motivation-behavioral skills (IMB) model provides a theoretical foundation for explaining and predicting individual health behaviors and has been widely applied in chronic disease self-management research [34,35]. Existing studies have confirmed that the IMB model can effectively predict medication adherence among older adults living with DM [36,37], offering scientific guidance for the development of intervention strategies. In recent years, video intervention has emerged as a new method of health communication. Existing studies have shown that videos not only effectively capture attention but also facilitate the understanding and retention of information [38]. Particularly within older adult populations, multimedia interventions have been demonstrated to overcome the limitations of traditional educational methods, improving the acquisition of health knowledge and enhancing patients' self-management capabilities [39,40]. Videos, delivered through convenient devices such as mobile phones, enable patients to view them anytime and anywhere, further reinforcing learning outcomes and improving medication adherence [41]. However, there is currently no research using video interventions to improve medication adherence among older adults living with T2DM. Therefore, exploring the application of IMB-based video interventions in this population and their potential to enhance medication adherence holds significant theoretical and practical importance. Based on this, we hypothesize that the Diabetes Little Helper video intervention will significantly improve medication adherence compared with standard care.

Methods

Ethical Considerations

This study received ethical approval from the Institutional Review Board of Universiti Putra Malaysia (JKEUPM-2023-1279) and Henan Provincial People's Hospital (20240107), and was registered with the Chinese Clinical Trial Registry (ChiCTR2400083282). Before data collection, the researcher obtained approval from the hospital and coordinated with relevant departments to ensure informed consent from participants and guide them to scan the QR code to follow the "Diabetes Little Helper" WeChat public account. All participant information was kept strictly confidential, and the questionnaire data were anonymized after collection to ensure that participants' identities could not be directly or indirectly identified. This study does not involve any monetary compensation or incentives for participants.

Study Design and Setting

This study was a parallel-group, cluster-randomized controlled trial (RCT) recruited older adults from 2 hospitals in Zhengzhou, Henan Province, China (Henan Provincial People's Hospital and Zhengzhou Central Hospital). Both hospitals are large, tertiary-level public general hospitals with an annual outpatient volume exceeding 1.1 million visits. Each hospital has over 70 clinical departments, including endocrinology, respiratory medicine, and cardiology, offering comprehensive medical services and a sufficient patient base for recruitment. The study spanned from April 2024 to June 2025, encompassing participant recruitment (from April to June 2024), intervention delivery, data collection, analysis, and manuscript preparation. The study was conducted and reported in accordance with the CONSORT (Consolidated Standards of Reporting Trials; checklist provided in [Multimedia Appendix 1](#)) guidelines. Further details of the study design and methodology are available in the published protocol in *BMJ Open* [42]. This study followed all specified procedures without any deviations from the protocol.

Participants

This study involved older adults diagnosed with T2DM who attended endocrinology outpatient clinics at 2 selected hospitals. Eligible individuals were identified from the outpatient population of each hospital and enrolled through simple random sampling. Participants must meet the following inclusion criteria: aged 60 years or older, diagnosed with T2DM [43], Chinese nationality, and able to understand Chinese, currently receiving at least one oral antidiabetic medication with a hemoglobin HbA_{1c} level of $\geq 7.0\%$, no cognitive impairment, and either the participant or their family member owns a smartphone and is able to use WeChat. Exclusion criteria include having severe comorbidities affecting major organs such as the heart, lungs, or kidneys, impairment in communication abilities, or participating in another study.

This cluster RCT study involves 2 hospitals, which were randomly assigned in a 1:1 allocation ratio to the control group (CG) and intervention group (IG) using a random number generator. Both hospitals used simple random sampling and a parallel design, recruiting 68 older adults living with T2DM. Randomization was conducted by the research coordinator using

a computer-generated random number sequence, with concealed allocation to prevent selection bias. The CG received standard nursing care, while the IG received additional video intervention. Due to the visible nature of the video intervention, the study was conducted as an open-label trial, meaning blinding was not feasible for the participants or executors. However, evaluators and statistical analysts remained blind to minimize bias. To minimize contamination, participants were selected from separate hospitals, and communication between the groups was restricted. After a 3-month follow-up, the CG received the same video intervention as the IG to ensure equal treatment.

The sample size for this study was calculated using the 2-mean sample size formula [44], based on the mean and SD of medication adherence for both CG and IG at postintervention and 3-month follow-up (29.15, SD 3.10; 31.27, SD 3.35; and 26.25, SD 2.01; 30.19, SD 2.41) [45,46]. Assuming a 2-sided test with a type I error rate (α) of 0.05, a power ($1-\beta$) of 80%, an 80% retention rate, and a design effect of 1.5, the required total sample size was calculated to be 68 participants per group.

Diabetes Little Helper Intervention Development

A health education intervention program based on the IMB theory model was developed for this study. The research team conducted 3 rounds of expert consensus meetings involving a multidisciplinary expert panel, which included 2 nursing experts with extensive clinical experience and expertise in video production, a biostatistician with a background in statistics for health interventions, and a family medicine specialist with expertise in DM management. The team collaboratively established a comprehensive educational framework covering 8 core topics related to DM medication management. These topics include proper medication storage and transportation, methods for identifying medication quality, disease management strategies, the importance of medication adherence, key medication precautions, common misconceptions about medications, self-management empowerment for older adults living with DM, and guidelines for blood glucose monitoring. For each topic, a 2-5 minute educational animation was developed using the “WanCai Animation Master” tool to visualize professional medical knowledge into easy-to-understand dynamic images [47]. [Table 1](#) shows the Diabetes Little Helper video intervention topic and plan.

Table 1. Topics and intervention plan of the Diabetes Little Helper video program for older adults living with type 2 diabetes mellitus in Henan, China.

Number	Week	Day of the week	IMB ^a	Topic	Video time
1	One	Tuesday	I	Storage & Traveling with Hypoglycemic Medications	3 min 31 s
2	One	Friday	I	How to Check Your Medications	3 min 20 s
3	Two	Tuesday	I	What to Do During Sick Days	2 min 57 s
4	Two	Friday	M	Importance of On-Time Medication	2 min 15 s
5	Three	Tuesday	M	Precautions for Taking Hypoglycemic Medication	1 min 53 s
6	Three	Friday	M	Correct Understanding of Hypoglycemic Medications	2 min
7	Four	Tuesday	B	Self-Empowerment & Support for Older Adults Living with DM	4 min 30 s
8	Four	Friday	B	Regular Blood Glucose Monitoring	3 min 6 s

^aIMB: information–motivation–behavioral skills.

Five nursing experts were invited to assess the content validity of the program based on the standards developed by Siti Noorkhairina et al [48]. These standards were specifically designed for evaluating video-based educational materials and cover various aspects of content quality, including media characteristics (title relevance and audio clarity), educational design (plot logic and age-appropriate language), and technical specifications (appropriate duration and information density). The Siti Noorkhairina et al standards provide a comprehensive framework for assessing the effectiveness of educational videos, ensuring that the content is clear, relevant, and engaging for the target audience. Experts rated 24 evaluation items based on these criteria to determine the content validity of the program. A 4-point Likert scale was used for the ratings. The Item-level Content Validity Index (I-CVI) for each of the 24 items was calculated by determining the proportion of experts who rated the item as relevant, with scores of 3 or 4 indicating relevance. For calculation, scores of 3 and 4 were recoded as “1.00” (indicating relevant), and scores of 1 and 2 were recoded as “0” (indicating non-relevant). The I-CVI for each item was then calculated as the proportion of experts who rated the item as “relevant”. A value of 1.00 for the I-CVI indicates unanimous agreement among the experts that each item was deemed relevant. The Scale-level Content Validity Index (S-CVI) was calculated by averaging the I-CVI scores across all items. A value of 1.00 for the S-CVI indicates that the overall scale was deemed fully valid by all experts. These results suggest that the content of the program was considered highly relevant and appropriate by all expert raters. Ten older adults living with T2DM were invited to participate in a face validity test, which focused on information reception indicators such as language comprehensibility, visual appeal, and pacing control. Based on patient feedback, the audiovisual elements of the videos were optimized.

Diabetes Little Helper Intervention Implementation

The intervention was implemented using a “standard care + digital health education” model, delivering content through the WeChat public account “Diabetes Little Helper.” During the 4-week intervention period, educational videos were scheduled to be released at 8 AM every Tuesday and Friday, with a total of 8 episodes. Patients could watch the videos at their convenience.

To ensure that patients successfully watched the intervention videos and to improve intervention quality, the research team took the following measures: (1) real-time monitoring of video viewership to track whether patients watched the videos on time, ensuring timely completion and optimizing the intervention strategy, (2) weekly WeChat reminders for patients to watch the new videos, along with contact information for researchers to provide immediate assistance, ensuring patients received the necessary information and encouraging participation, (3) weekly phone follow-ups to check patients’ video-watching progress, particularly focusing on those who missed videos, researchers would inquire about reasons for nonviewing and provide personalized help to ensure patient involvement, (4) personalized support for patients with special circumstances or frequent video nonviewing, including simple viewing guides and remote technical support to resolve technical issues, ensuring patients could watch the videos without difficulty.

Development of a Questionnaire to Evaluate Medication Adherence, Knowledge, Attitude, Behavior, Belief, and Social Support

A self-developed questionnaire was used to collect data from participants, covering 8 aspects. A detailed overview of all outcome measures used in this study can be found in the study protocol [42]. The measures analyzed in this manuscript are described below.

Sociodemographic and Disease-Related Characteristics

This study collected sociodemographic characteristics (such as age, sex, and marital status) as well as disease-related variables (such as the duration of T2DM, family history, and adverse medication reaction).

Medication Adherence

Medication adherence is assessed using the Self-Efficacy for Appropriate Medication Use Scale [49], which includes 13 items, rated on a 3-point Likert scale, with a total score range of 13 to 39. Higher scores indicate better medication adherence. The Cronbach α value of the scale is 0.934 [49,50].

Medication Knowledge, Attitude, and Behavior

The medication knowledge, attitude, and behavior questionnaires are used to measure patients’ knowledge, attitudes, and

behaviors regarding medication. The test-retest reliability for each dimension ranges from 0.854 to 0.920, with an overall test-retest reliability of 0.868 [51]. The knowledge questionnaire consists of 17 items, with a total score range of 0 to 17, where higher scores indicate a greater level of medication knowledge. The medication attitude questionnaire includes 10 items, with a total score range of 10 to 50, where higher scores reflect a more positive attitude toward safe medication use. The medication behavior questionnaire consists of 13 items, with scores ranging from 9 to 40, where higher scores indicate safer medication behaviors.

Medication Belief

The medication belief questionnaire is used to assess the personal medication beliefs of older adults living with DM [52]. The questionnaire consists of 10 items, divided into 2 dimensions, medication necessity and medication concern, with scores ranging from 1 to 5. Higher scores indicate stronger medication beliefs. The Cronbach α value for the questionnaire is 0.724, with Cronbach α values of 0.749 and 0.796 for the 2 dimensions, respectively.

Social Support

The social support questionnaire is used to assess the support patients receive across multiple dimensions [53]. This scale includes 4 dimensions, with a total of 19 items, and the total score ranges from 19 to 95. Higher scores indicate higher levels of social support among the older adults. The questionnaire demonstrates good reliability and validity, with a Cronbach α value of 0.803 and a content validity index of 0.958 [53].

To ensure the content validity of the questionnaire assessing medication adherence, knowledge, attitude, behavior, belief, and social support, 5 experts reviewed it to confirm that the content aligned with the research objectives and that the questions were relevant and representative of the study. Based on expert feedback, some questions were adjusted to ensure they accurately measured the intended content. The I-CVI and the S-CVI of the questionnaire were both calculated to be 1, indicating strong content validity. Additionally, to assess the face validity of the questionnaire, it was presented to 10 older adults living with T2DM, who provided feedback on the clarity and appropriateness of the language used in the questions. Based on their feedback, the wording of some questions was revised for better clarity and suitability. The revised questionnaire was found to be relevant, user-friendly, and suitable for this population.

Data Collection

Data collection occurred at 3 time points: baseline, postintervention, and 3-month follow-up. The questionnaire was available in both paper and electronic formats. Baseline data were collected between April and June 2024. Researchers conducted on-site checks to ensure the quality of questionnaire completion, confirming that all questions were fully answered and met the required standards. For older adult participants who had difficulty filling out or understanding the questions, standardized instructions were provided to help them interpret the content and complete the questionnaire correctly. During

the postintervention and follow-up periods, the electronic questionnaire was sent to participants via a WeChat official account, with researchers assisting through WeChat or phone calls to ensure a high response rate and data quality. After collecting the questionnaires, researchers reviewed and processed any inconsistent or missing data to ensure completeness. Data were entered by 2 research assistants and imported into SPSS (version 29.0; IBM Corp) software for analysis. To reduce entry errors, all data were proofread twice after input to ensure consistency with the original questionnaires. Data from the electronic questionnaires were directly imported into SPSS.

Data Analysis

Data analysis was performed using SPSS Statistics, following the intention-to-treat principle. Missing data were handled using the last observation carried forward (LOCF) method. A significance level was set at $P<.05$. Histograms with normal curves were used to assess the normality of continuous variables. For normally distributed variables, data are expressed as mean (SD), while not normally distributed variables are presented as median and IQR. Categorical variables are reported as frequencies and percentages (%).


For baseline group comparisons, the Pearson chi-square test and chi-square test with continuity correction were applied for categorical variables. Independent samples t test and Mann-Whitney U test were used for continuous variables. To assess the intervention effects, generalized estimating equation models with an unstructured working correlation matrix were used to analyze changes in medication adherence, knowledge, attitude, behavior, belief, and social support scores. The models compared the changes between the IG and CG at baseline, postintervention, and at the 3-month follow-up, with time, group, and their interaction as independent variables. The interaction term was used to assess whether there were different changes between the groups at different time points. Significant differences between the groups were adjusted for as covariates in the final model.

Results

Participant Flow

The IG consisted of 68 participants randomly selected from a pool of 110 eligible patients in one hospital, while the CG included 68 participants randomly selected from a pool of 100 eligible patients in the other hospital. Compared with the web-based questionnaire, 26 (29.0%) participants in the IG and 20 (38.0%) participants in the CG chose to complete the paper questionnaire. Both groups had an initial retention rate of 100% (n=68). After the intervention, 3 participants dropped out of the IG, leading to a retention rate of 95.6% (n=65). In the CG, one participant did not participate due to health issues, and another withdrew, resulting in a retention rate of 97.1% (n=66). Following a 3-month follow-up, 2 participants left the IG, giving a retention rate of 92.6% (n=63). In the CG, 3 participants withdrew, and one could not be contacted, leading to a retention rate of 92.2% (n=62). [Figure 1](#) shows the data collection flow according to the CONSORT guidelines.

Figure 1. CONSORT (Consolidated Standards of Reporting Trials) flow diagram for a cluster randomized controlled trial on the effectiveness of the Diabetes Little Helper intervention video among older adults living with type 2 diabetes mellitus.



Participant Characteristics

Sociodemographic and Disease-Related Characteristics Between the IG and CG at Baseline

At baseline, a comparison of sociodemographic and disease-related characteristics between the IG and CG showed no statistically significant differences ($P>.05$). The sex distribution was nearly identical, with 51.5% (n=35) in the IG and 50.0% (n=34) in the CG being male. Most participants lived in urban areas (IG: 38/68, 55.9%; CG: 42/68, 61.8%) and resided with family members (IG: 62/68, 91.2%; CG: 60/68, 88.2%). A large portion of participants were married (IG: 50/68, 73.5%; CG: 52/68, 76.5%). All participants had children, and education

levels were primarily at the junior high school (IG: 22/68, 32.4%; CG: 10/68, 14.7%) and high school (IG: 21/68, 30.9%; CG: 22/68, 32.4%) levels. Additionally, a significant portion of participants did not use smartphones independently (IG: 15/68, 22.1%; CG: 10/68, 14.7%). The mean and SD for BMI and the duration of T2DM were as follows: IG 24.04 (SD 3.475), CG 24.08 (SD 3.428); IG 14.76 (SD 8.381), CG 14.19 (SD 7.658). Most participants used oral medications (IG: 37/68, 54.4%; CG: 35/68, 53.3%), and the proportion of family members without diabetes was similar (IG: 26/68, 33.3%; CG: 23/68, 29.5%). The most common adverse reactions were hypoglycemia (IG: 21/68, 30.9%; CG: 16/68, 26.5%) and digestive system issues (IG: 13/68, 10.1%; CG: 10/68, 14.7%). Details are provided in Table 2.

Table 2. Comparison of sociodemographic characteristics between the intervention group (IG) and control group (CG) at baseline among older adults living with type 2 diabetes mellitus (T2DM) in Henan, China (N=136).

Variable	IG (n=68)	CG (n=68)	Chi-square (df) ^{a,b}	t test (df) ^c	Z ^d	P value
Age (years), median (IQR)	67.5 (63.3-71)	66.0 (69.8-63)	— ^e	—	-0.901 ^d	.37
Sex, n (%)			0.029 (1) ^a	—	—	.86
Male	35 (51.5)	34 (50.0)				
Female	33 (48.5)	34 (50.0)				
Residence, n (%)			0.486 (1) ^a	—	—	.49
Countryside	30 (44.1)	26 (38.2)				
City	38 (55.9)	42 (61.8)				
Marital status, n (%)			2.039 (2) ^a	—	—	.36
Married	50 (73.5)	52 (76.5)				
Divorced	3 (4.4)	6 (8.8)				
Widowed	15 (22.1)	10 (14.7)				
Living arrangement, n (%)			0.319 (1) ^a	—	—	.57
Living alone	6 (8.8)	8 (11.8)				
Living with family	62 (91.2)	60 (88.2)				
Education level, n (%)			7.344 (5) ^a	—	—	.20
Illiterate	4 (5.9)	6 (8.8)				
Primary school	9 (13.2)	14 (20.6)				
Junior high school	22 (32.4)	10 (14.7)				
High school	21 (30.9)	22 (32.4)				
Bachelor degree	12 (17.6)	15 (22.1)				
Postgraduate and above	0 (0)	1 (1.5)				
Have children, n (%)			—	—	—	—
Yes	68 (100)	68 (100)				
No	0 (0)	0 (0)				
Smoke, n (%)			4.946 (3) ^a	—	—	.18
Yes, smoker	11 (16.2)	19 (27.9)				
No, never smoke	38 (55.9)	39 (57.4)				
Used smoke, quite now	13 (19.1)	7 (10.3)				
Occasional smoker	6 (8.8)	3 (4.4)				
Smoke year, median (IQR)	0 (0-30)	0 (0-34.3)	—	—	-0.024 ^d	.98
Drink, n (%)			2.079 (3) ^a	—	—	.56
Yes, drinker	8 (11.8)	14 (20.6)				
No, never drink	35 (51.5)	33 (48.5)				
Used drink, quite now	9 (13.2)	7 (10.3)				
Occasional drinker	16 (23.5)	14 (20.6)				
Drink year, median (IQR)	0 (0-39.3)	15 (0-40)	—	—	-0.398 ^d	.69
Personal income, n (%)			0.256 (1) ^a	—	—	.61
Have income	58 (85.3)	60 (88.2)				
No income	10 (14.7)	8 (11.8)				

Variable	IG (n=68)	CG (n=68)	Chi-square (df) ^{a,b}	t test (df) ^c	Z ^d	P value
Personal income (RMB) ^{f,g} , median (IQR)	4000 (2800-5375)	4000 (2850-5375)	—	—	-0.264 ^d	.79
Household income, n (%)			0.000 (1) ^b	—	—	>.99
Have income	66 (97.1)	66 (97.1)				
No income	2 (2.9)	2 (2.9)				
Household income (RMB) ^{f,g} , median (IQR)	8000 (7000-10,750)	8000 (6000-10,000)	—	—	-0.389 ^d	.70
Occupational status, n (%)			1.578 (3) ^a	—	—	.66
Employed	9 (13.2)	10 (14.7)				
Unemployed	6 (8.8)	8 (11.8)				
Retired	40 (58.8)	42 (61.8)				
Others	13 (19.1)	8 (11.8)				
Medical payment method, n (%)			0.342 (3) ^a	—	—	.93
Self-paid	1 (1.5)	2 (2.9)				
Medical insurance	61 (89.7)	60 (88.2)				
Commercial insurance	5 (7.4)	5 (7.4)				
Others	1 (1.5)	1 (1.5)				
BMI (kg/m²), mean (SD)	24.04 (3.475)	24.08 (3.428)	—	-0.066 (134) ^c	—	.65
<18.5	4 (5.9)	4 (5.9)				
18.5-23.9	30 (44.1)	27 (39.7)				
24-27.9	27 (39.7)	29 (42.6)				
≥28	7 (10.3)	8 (11.8)				
Smartphone usage, n (%)			1.225 (1) ^a	—	—	.27
Yes	53 (77.9)	58 (85.3)				
No	15 (22.1)	10 (14.7)				
T2DM duration, mean (SD)	14.76 (8.381)	14.19 (7.658)	—	-0.063 (134) ^c	—	.55
Family history, n (%)			0.353 (2) ^a	—	—	.84
Yes	23 (33.8)	26 (38.2)				
No	28 (41.2)	25 (36.8)				
Do not know	17 (25.0)	17 (25.0)				
Family member has diabetes mellitus, n (%)			6.543 (6) ^a	—	—	.37
No	26 (33.3)	23 (29.5)				
Father	9 (11.5)	17 (21.8)				
Mother	10 (12.8)	10 (12.8)				
Sibling	11 (14.1)	5 (6.4)				
Grandparents	2 (2.6)	5 (6.4)				
Do not know	18 (23.1)	17 (21.8)				
Other relative	2 (2.6)	1 (1.3)				
Combination disease						
Hypertension, n (%)			0.034 (1) ^a	—	—	.85
No	21 (30.9)	22 (32.4)				
Yes	47 (69.1)	46 (67.6)				

Variable	IG (n=68)	CG (n=68)	Chi-square (df) ^{a,b}	t test (df) ^c	Z ^d	P value
Coronary heart disease, n (%)			0.873 (1) ^a	—	—	.35
No	50 (73.5)	45 (66.2)				
Yes	18 (26.5)	23 (33.8)				
Chronic heart failure, n (%)			0.831 (1) ^b	—	—	.36
No	64 (94.1)	67 (98.5)				
Yes	4 (5.0)	1 (1.5)				
Stroke, n (%)			0.133 (1) ^b	—	—	.71
No	63 (92.6)	65 (95.6)				
Yes	5 (7.4)	3 (4.4)				
Kidney disease, n (%)			0.831 (1) ^b	—	—	.36
No	64 (94.1)	67 (98.5)				
Yes	4 (5.9)	1 (1.5)				
Other diseases, n (%)			0.067 (1) ^a	—	—	.80
No	60 (88.2)	59 (86.8)				
Yes	8 (11.8)	9 (13.2)				
Type of medication, n (%)			0.216 (2) ^a	—	—	.90
Oral	37 (54.4)	35 (53.3)				
Insulin	0 (0)	0 (0)				
Both	28 (41.2)	29 (42.6)				
Others	3 (4.4)	4 (5.9)				
Kind of medication, median (IQR)	3.0 (3-4.8)	3.0 (2-5)	—	—	-0.401 ^d	.69
Adverse reactions						
Hypoglycemia, n (%)			0.324 (1) ^a	—	—	.57
No	47 (69.1)	50 (73.5)				
Yes	21 (30.9)	16 (26.5)				
Digestive system, n (%)			0.471 (1) ^a	—	—	.49
No	55 (80.9)	58 (85.3)				
Yes	13 (10.1)	10 (14.7)				
Chronic heart failure, n (%)			0.133 (1) ^b	—	—	.72
No	63 (92.6)	65 (95.6)				
Yes	5 (7.4)	3 (4.4)				
Allergic reaction, n (%)			0.000 (1) ^b	—	—	>.99
No	66 (97.1)	65 (97.1)				
Yes	2 (2.9)	2 (2.9)				
Liver damage, n (%)			1.681 (1) ^a	—	—	.20
No	62 (83.8)	69 (92.0)				
Yes	12 (16.2)	6 (8.0)				
Kidney damage, n (%)			0.319 (1) ^a	—	—	.57
No	60 (88.2)	62 (91.2)				
Yes	8 (11.8)	6 (8.8)				

Variable	IG (n=68)	CG (n=68)	Chi-square (df) ^{a,b}	t test (df) ^c	Z ^d	P value
Others diseases, n (%)			0.000 (1) ^b	—	—	>.99
No	66 (97.1)	65 (95.6)				
Yes	2 (2.9)	3 (4.4)				

^aPearson chi-square.^bContinuity correction.^cIndependent sample t test.^dMann-Whitney U test.^eNot applicable.^f1 RMB ≈ RM 0.61 (November 08, 2024).^g1 RMB ≈ US \$0.14 (January 07, 2026).

Medication Adherence, Medication Knowledge, Medication Attitude, Medication Behavior, Medication Belief, and Social Support Between the IG and CG at Baseline

There were no significant differences between the IG and CG of medication adherence (23.71, SD 5.725 vs 24.01, SD 5.700; $t_{134}=-0.315$; $P=.820$), medication knowledge (63.41, SD 19.145

vs 62.37, SD 20.202; $t_{134}=0.308$; $P=.547$), medication attitude (35.76, SD 3.801 vs 36.15, SD 4.129; $t_{134}=-0.562$; $P=.568$), medication behavior (29.62, SD 4.381 vs 29.13, SD 4.029; $t_{134}=0.672$; $P=.468$), medication belief (3.00, SD 3.515 vs 2.94, SD 3.777; $t_{134}=0.094$; $P=.520$) and social support (69.62, SD 11.402 vs 68.22, SD 10.935; $t_{134}=0.729$; $P=.805$) at baseline (Table 3).

Table 3. Total score of medication adherence, knowledge, attitude, behavior, belief, and social support between the intervention group (IG) and control group (CG) at baseline among older adults living with type 2 diabetes mellitus in Henan, China.

Outcomes (range) ^a	IG, mean (SD)	CG, mean (SD)	t test(df)	P value ^b
Medication adherence (13 to 39)	23.71 (5.725)	24.01 (5.700)	-0.315 (134)	.82
Medication knowledge (0 to 100)	63.41 (19.145)	62.37 (20.202)	0.308 (134)	.55
Medication attitude (10 to 50)	35.76 (3.801)	36.15 (4.129)	-0.562 (134)	.57
Medication behavior (9 to 40)	29.62 (4.381)	29.13 (4.029)	0.672 (134)	.47
Medication belief (-25 to +25)	3.00 (3.515)	2.94 (3.777)	0.094 (134)	.52
Social support (19 to 95)	69.62 (11.402)	68.22 (10.935)	0.729 (134)	.81

^aHigher scores of outcomes indicate better medication adherence, knowledge, attitude, behavior, belief, and social support.^bP value with $P>.05$ indicates that there are no significant differences between the IG and CG for the measured outcomes.

Outcomes

Overview

This study includes 6 outcome variables, including medication adherence, medication knowledge, medication attitude,

medication behavior, medication beliefs, and social support. Given the absence of significant effects, no covariates were incorporated into the final model. Generalized estimating equation was used to investigate the changes in outcomes between IG and CG across 3 time points. The results are shown in Table 4.

Table 4. Comparison of medication adherence, medication knowledge, medication attitude, medication behavior, medication belief, and social support scores between the intervention group (IG) and control group (CG) across time points using generalized estimating equations among older adults living with type 2 diabetes mellitus in Henan, China.

Variable	Medication knowl-edge ^a		Medication attitude ^b		Social support ^c		Medication belief ^d		Medication behav-ior ^e		Medication adher-ence ^f	
	β (95% CI)	P value	β (95% CI)	P value	β (95% CI)	P value	β (95% CI)	P value	β (95% CI)	P value	β (95% CI)	P value
Group effect												
CG	Ref ^g	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
IG	7.887 (3.428 to 12.345)	.001 ^h	2.465 (1.466 to 3.464)	<.001 ^h	1.277 (-4.771 to 7.352)	.679	1.845 (1.078 to 2.613)	<.001 ^h	2.731 (1.639 to 3.823)	<.001 ^h	2.288 (0.681 to 3.894)	.005 ^h
Time effect												
T0 ⁱ	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
T1 ^j	7.093 (4.564 to 9.623)	<.001 ^h	3.103 (2.370 to 3.836)	<.001 ^h	0.397 (-0.564 to 1.358)	.418	1.632 (1.125 to 2.140)	<.001 ^h	2.441 (1.848 to 3.034)	<.001 ^h	2.601 (1.858 to 3.363)	<.001 ^h
T2 ^k	4.844 (2.462 to 7.227)	<.001 ^h	1.662 (1.059 to 2.264)	<.001 ^h	-0.574 (-1.491 to 0.344)	.221	0.588 (0.062 to 1.114)	.028 ^h	1.125 (0.586 to 1.664)	<.001 ^h	1.684 (0.958 to 2.409)	<.001 ^h
Timepoint×Group effect												
T0 × CG	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
T1 × IG	11.592 (6.923 to 16.260)	<.001 ^h	5.467 (4.531 to 6.763)	<.001 ^h	0.008 (-1.834 to 2.011)	.928	2.882 (1.990 to 3.775)	<.001 ^h	4.176 (3.220 to 5.133)	<.001 ^h	4.956 (3.702 to 6.210)	<.001 ^h
T2 × IG	6.055 (1.401 to 10.710)	.011 ^h	3.059 (1.969 to 4.149)	<.001 ^h	-0.147 (-1.982 to 1.688)	.875	1.882 (0.880 to 2.885)	<.001 ^h	2.426 (1.429 to 3.424)	<.001 ^h	3.691 (2.379 to 5.003)	<.001 ^h

^aGroup: QIC=105,178.155, QICC=105,173.944, time: QIC=106,219.108, QICC=106,219.108, time × group: QIC=99,054.337, QICC=99,054.337.

^bGroup: QIC=5783.910, QICC=5780.419, time: QIC=5787.824, QICC=5787.824, time × group: QIC=4587.706, QICC=4687.706.

^cGroup: QIC=37,306.144, QICC=36,267.594, time: QIC=37,378.507, QICC=37,378.597, time × group: QIC=37,198.191, QICC=37,198.191.

^dGroup: QIC=3561.609, QICC=3558.406 time: QIC=3643.971, QICC=3643.971, time × group: QIC=3227.618, QICC=3227.618.

^eGroup: QIC=6009.207, QICC=6004.590, time: QIC=6301.456, QICC=6301.456, time × group: QIC=5304.176, QICC=5304.176.

^fGroup: QIC=11,557.678, QICC=11,551.984 time: QIC=11,731.963, QICC=11,731.963, time × group: QIC=10,617.505, QICC=10,617.505.

^gRef: Reference group.

^hSignificant at $P<.05$.

ⁱT0: baseline.

^jT1: postintervention.

^kT2: 3-month follow up.

Primary Outcome

The IG exhibited a significantly higher medication adherence score compared with the CG, with a mean difference of 2.288 points ($\beta=2.288$, 95% CI 0.681-3.894, $P=.005$). Participants demonstrated significant improvements in medication adherence both immediately after the intervention ($\beta=2.610$, 95% CI 1.858-3.363, $P<.001$) and at the 3-month follow-up ($\beta=1.684$, 95% CI 0.958-2.409, $P<.001$) when compared with baseline. The IG showed a significantly higher medication adherence score postintervention, with a difference of 4.956 points

compared with the CG at baseline ($\beta=4.956$, 95% CI 3.702-6.210, $P<.001$). At the 3-month follow-up, the IG maintained a significantly higher score than the CG at baseline, with a difference of 3.691 points ($\beta=3.691$, 95% CI 2.379-5.003, $P<.001$).

Secondary Outcomes

Compared with the CG, the IG showed a significant improvement in medication knowledge score, with a postintervention score higher by 7.887 points ($\beta=7.887$, 95% CI 3.428-12.345, $P=.001$). Compared with baseline, the

medication knowledge score of the participants increased by 7.093 points after the intervention and by 4.844 points at the 3-month follow-up ($\beta=7.093$, 95% CI 4.564-9.623, $P<.001$; $\beta=4.844$, 95% CI 2.462-7.227, $P<.001$). After the intervention, the medication knowledge score of the IG group was significantly higher than the CG group at baseline ($\beta=11.592$, 95% CI 6.923-16.260, $P<.001$). At the 3-month follow-up, the medication knowledge score of the IG group was 6.055 points higher than that of the CG group at baseline ($\beta=6.055$, 95% CI 1.401-10.710, $P=.011$).

The medication attitude score of the IG was significantly higher than that of CG, with a difference of 2.465 points ($\beta=2.465$, 95% CI 1.466-3.464, $P<.001$). Compared with the baseline, the medication attitude score of the participants significantly increased by 3.103 points after the intervention and by 1.662 points at the 3-month follow-up, respectively ($\beta=3.103$, 95% CI 2.370-3.836, $P<.001$; $\beta=1.662$, 95% CI 1.059-2.264, $P<.001$). After the intervention, the medication attitude score of the IG group was significantly higher than that of the CG group at baseline, with a difference of 5.467 points ($\beta=5.467$, 95% CI 4.531-6.763, $P<.001$). At the 3-month follow-up, the medication attitude score of the IG group was 3.059 points higher than that of the CG group at baseline ($\beta=3.059$, 95% CI 1.969-4.149, $P<.001$).

The IG showed a significantly higher medication behavior score compared with the CG, with a mean difference of 2.731 points ($\beta=2.731$, 95% CI 1.639-3.823, $P<.001$). Participants demonstrated significant improvements in medication behavior relative to baseline, both immediately after the intervention ($\beta=2.441$, 95% CI 1.848-3.034, $P<.001$) and at the 3-month follow-up ($\beta=1.125$, 95% CI 0.586-1.664, $P<.001$). Postintervention, the IG scored 4.176 points higher than the CG at baseline ($\beta=4.176$, 95% CI 3.220-5.133, $P<.001$). At the 3-month follow-up, the IG also outperformed the CG at baseline, with a difference of 2.426 points ($\beta=2.426$, 95% CI 1.429-3.424, $P<.001$).

The IG demonstrated a significantly higher medication belief score than the CG, with an estimated difference of 1.845 points ($\beta=1.845$, 95% CI 1.078-2.613, $P<.001$). Compared with baseline, participants showed a significant increase in medication belief score both immediately after the intervention ($\beta=1.632$, 95% CI 1.125-2.140, $P<.001$) and at the 3-month follow-up ($\beta=0.588$, 95% CI 0.062-1.114, $P=.028$). Furthermore, in the analysis of the interaction between time and group, the IG at postintervention scored significantly higher than the CG at baseline, with a difference of 2.882 points ($\beta=2.882$, 95% CI 1.990-3.775, $P<.001$). Similarly, at the 3-month follow-up, the IG maintained a significantly higher score than the CG at baseline ($\beta=1.882$, 95% CI 0.880-2.885, $P<.001$).

However, social support did not reach statistical significance in terms of time, group, and the interaction between time and group, in either the IG or CG group ($P>.05$).

Discussion

Principal Findings

Research has shown that the IMB model can effectively explain, predict, and improve medication adherence among older adults living with chronic diseases [54,55]. Based on previous research findings, this study combined the IMB model to develop an animated intervention video called “Diabetes Little Helper” which was disseminated through the WeChat platform, further validating the model’s applicability in older adults. As with the results of this study, a quasi-experimental study by Mirzaei-Alavijeh et al [56], based on the IMB model, significantly improved medication adherence in older adults living with T2DM through 6 face-to-face educational sessions, further supporting the effectiveness of the IMB model. This study, through the WeChat platform, disseminates educational information in video format, providing new evidence and intervention pathways for improving medication adherence among older adults living with T2DM.

A notable proportion of participants reported not using smartphones independently. This finding is significant, as it could influence the overall effectiveness of the intervention. However, it is important to note that all participants in this study either owned a smartphone and used WeChat or received assistance from family members to participate. Nonetheless, the involvement of family members could be seen as a limitation, as it may affect the autonomy of older adults and potentially influence their overall engagement with the intervention. Additionally, reliance on family assistance raises concerns about the generalizability and long-term feasibility of the intervention, particularly for older adults who may not have family members available to offer support. To address this, future research could explore alternative strategies to enhance technological support for older adults, such as simplified user interfaces or targeted training programs. These approaches could ensure broader accessibility and improve the effectiveness of similar interventions in diverse populations.

Participants’ medication adherence score showed significant improvement following the intervention, a result that mirrors outcomes seen in other studies using different methods. For instance, mobile apps were used to provide educational information to family members, who in turn helped older adults living with DM complete self-management tasks, pharmacy students conducted motivational interviewing through phone calls to enhance medication adherence, while pharmacists used apps, WeChat public accounts, WeChat groups, and both web-based and offline lectures to improve medication adherence among older adults living with DM [30,31,33]. These interventions effectively increased medication adherence in older adults living with DM, though they also presented certain challenges. Relying on family members to convey information poses the risk of information distortion and places psychological pressure on the family. Dependence on pharmacy students for motivational interviewing might lead to insufficient mastery of communication and problem-solving skills, potentially affecting the interview’s effectiveness. Although pharmacists use a combination of web-based and offline platforms to provide

comprehensive services, the use of multiple channels may confuse older adults, especially those less familiar with digital technologies. In contrast, this study directly engaged patients via WeChat, eliminating hierarchical errors in information transmission and avoiding family involvement in the medical process. The professionally designed animated videos ensured the accuracy and coherence of the information, minimizing human bias. Moreover, the approach did not require the development of complex programs or offline services, thus saving both manpower and financial resources.

This study demonstrated that the Diabetes Little Helper video significantly improved participants' medication knowledge score, which is consistent with previous research findings [57]. Compared with the one-on-one face-to-face educational model used by Yang et al [57], this study overcame the limitations of time and location while also saving human resources. Xiong and Wan [58] also improved older adult participants' medication knowledge score by sending text and images via the WeChat platform. In comparison, the animated video used in this study not only incorporated the advantages of text and images but also effectively captured patients' attention through its vivid and engaging format, helping viewers better understand concepts and stimulate cognitive responses. The use of animated videos has been shown to be a more attractive and dynamic method, aiding viewers in gaining a deeper understanding of health education content [59]. Future intervention research could explore how to combine face-to-face education with digital video interventions, leveraging the strengths of both traditional and modern educational methods to further enhance patients' medication knowledge scores.

Participants' medication attitudes were effectively improved, as agreed with Chen et al [60], who used a multidimensional, multiscenario intervention approach, which also successfully enhanced medication attitudes. However, their method requires substantial human resources and high costs, making it challenging to implement in regions with limited health care resources. Zhou [61] conducted an intervention through community health service centers, regularly monitoring patients' medication levels, metabolism, and relevant physiological indicators to guide medication adjustments, which improved medication attitudes in older adults. In contrast, the intervention model in this study overcomes regional and resource limitations through digital means, making it simple and feasible. Each intervention method has its unique advantages and suitable contexts. Future research should flexibly select intervention strategies based on the specific characteristics of hospitals and patients, and integrate multiple approaches to more effectively improve medication attitudes in older adults.

The intervention also had a positive impact on improving participants' medication behavior score, in line with the findings of Wang et al [62], whose study increased medication adherence through personalized plans and continuous optimization. However, their approach relied heavily on frequent face-to-face reminders, which may have provoked resistance from some patients. In this study, patients were able to choose their learning time and frequency, which reduced resistance and improved psychological acceptance. Moreover, the intervention program by Wan et al [63] required 50 participants to provide more

tailored health education and medication management. Although it also led to some improvement in medication behavior, the management process was relatively complex and added additional costs. Moreover, staff turnover, absenteeism, and communication difficulties could negatively impact the effectiveness of the intervention.

The results of this study also indicate a significant improvement in participants' medication beliefs, aligning with findings from previous research [64,65]. These studies used interviews or multidisciplinary collaboration (involving family doctors, pharmacists, and nurses) to integrate and guide medication management. However, these approaches are typically limited to stable patients who can attend interviews and are not applicable to older adults living at home. Additionally, team collaboration demands more human resources. However, this study focused on broadening medication knowledge and promoting self-management, encouraging older adults to independently adjust their medication attitudes.

This study did not show a significant effect on improving participants' social support scores. This finding is consistent with the results of Yang et al [57], who also did not observe significant improvements in social support after using traditional intervention methods, such as face-to-face education, interviews, phone communication, and record-keeping. One possible reason for this is that the development of social support requires sustained intervention over more than 6 months [66]. Additionally, some studies have shown that including education for patients' family members and facilitating web-based interactive communication effectively improved social support among older adults [67,68]. Future research could integrate interactive modules, such as involving family members in the intervention plan, promoting web-based communication among patients, and combining community nursing, to further strengthen the patient's social support network and enhance the overall intervention effectiveness.

This study is the first to develop an animated video intervention to improve medication adherence in older adults living with T2DM, expanding the application of this model in medication management for older adults living with DM and providing new insights for chronic disease management. Moreover, this study innovatively used the WeChat public platform to deliver animated video intervention content to older adults living with DM. This approach not only overcomes the time and space limitations of traditional health education but also leverages the widespread use and interactivity of the WeChat platform, enabling continuous health interventions. As a result, it significantly increased the accessibility of intervention content and enhanced patient acceptance. Patients could repeatedly watch the intervention videos in their daily lives, which helped reinforce memory and promote behavior change.

Limitations and Future Research

While the findings of this study provide valuable insights into the effectiveness of the intervention, several limitations must be acknowledged. First, the reliance on self-reported adherence introduces potential biases, such as over-reporting, underreporting, and recall bias. These biases can compromise the accuracy of adherence measurements and may not fully

reflect the participants' true behaviors. Future studies could incorporate objective measures of adherence, such as electronic monitoring or biomarkers, to reduce these biases and provide a more accurate picture of adherence. Second, while the 3-month follow-up period allowed us to assess the short-term effects of the intervention, it was insufficient to evaluate the long-term sustainability of the intervention's impact. Future studies should aim for extended follow-up periods to gain a deeper understanding of the long-term benefits and challenges of such interventions. Furthermore, the inability to blind participants due to the visible nature of the intervention video may have introduced bias, as participants were aware of their intervention condition, which could have influenced their responses or behaviors. To mitigate this in future studies, an RCT design with blinding could be implemented, or a different form of intervention that is less visible could be explored.

Adherence monitoring measures, though designed to ensure compliance, may have inadvertently influenced engagement and adherence, thereby introducing additional intervention effects. Future studies should consider monitoring approaches that minimize such influences. In terms of data handling, this study used the LOCF method to address missing data. Although LOCF is computationally simple and commonly used in short-term studies, it assumes that missing data are equivalent to the last observed value, which may lead to an underestimation of variability in the results. If participants drop out due to

deteriorating health, LOCF may fail to capture this change, potentially overestimating the intervention effect. Despite these limitations, LOCF was considered an appropriate choice for this study. Future research could consider exploring other advanced methods for handling missing data, such as multiple imputation, to improve the accuracy of data analysis.

Conclusions

This study evaluated the impact of a WeChat-based Diabetes Little Helper video intervention on medication adherence and medication-related outcomes in older adults living with T2DM. The results indicated that the intervention had a significant positive effect on improving patients' medication adherence, knowledge, attitude, behavior, and belief. However, it did not significantly enhance the patients' level of social support. Building on these findings, future research could expand to include more regions and health care institutions and conduct multicenter RCTs to verify the applicability and effectiveness of the Diabetes Little Helper video intervention across different geographic and cultural contexts. This would help to further improve the external validity and reliability of the study's findings. Moreover, future studies could explore the integration of more advanced health tools, such as smart wristbands and smart pillboxes, to monitor the health status and medication adherence of older adults living with T2DM in real time, thereby providing additional support for personalized interventions and data analysis.

Acknowledgments

The authors gratefully acknowledge the support of Universiti Putra Malaysia and 2 hospitals in Henan province, China, for their contributions to this research. The authors also thank Universiti Putra Malaysia for the publication fees support. We also extend our heartfelt thanks to all the experts who offered their valuable guidance, professional insights, and feedback, which were instrumental in enhancing the quality and impact of this intervention study. All authors approved this manuscript for publication.

Funding

This study did not receive research funding from any public, commercial, or nonprofit funding agencies. The publication fees are supported by Universiti Putra Malaysia.

Data Availability

The datasets generated or analyzed during this study are available in the Mendeley data repository.

Authors' Contributions

MW, PYL, KL, SNS, HZT, and QHJ contributed to the conceptualization and design of the study. Data collection was carried out by MW, QHJ, LLH, ZYZ, and YL. MW and PYL conducted the data analysis. Interpretation of the results was performed by MW, PYL, SNS, and HZT. MW was responsible for drafting and revising the manuscript. Supervision was provided by PYL, KL, SNS, and HZT. Project administration was managed by PYL, SNS, and HZT. Ethical approval was obtained by MW and QHJ.

Conflicts of Interest

None declared.

Multimedia Appendix 1

CONSORT eHEALTH checklist (V 1.6.1).

[[PDF File \(Adobe PDF File\), 1108 KB-Multimedia Appendix 1](#)]

References

1. Sun, Wen H, Liu X, Ma Y, Jang J, Yu C. Time trends in type 2 diabetes mellitus incidence across the BRICS from 1990 to 2019: an age-period-cohort analysis. *BMC Public Health*. 2022;22(1):65. [FREE Full text] [doi: [10.1186/s12889-021-12485-y](https://doi.org/10.1186/s12889-021-12485-y)] [Medline: [35012503](#)]
2. Hossain MJ, Al-Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: early detection should be focused. *Health Sci Rep*. 2024;7(3):e2004. [FREE Full text] [doi: [10.1002/hsr2.2004](https://doi.org/10.1002/hsr2.2004)] [Medline: [38524769](#)]
3. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. Erratum to "IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045" [Diabetes Res. Clin. Pract. 183 (2022) 109119]. *Diabetes Res Clin Pract*. 2023;204:110945. [doi: [10.1016/j.diabres.2023.110945](https://doi.org/10.1016/j.diabres.2023.110945)] [Medline: [37863776](#)]
4. Sinclair A, Saeedi P, Kaundal A, Karuranga S, Malanda B, Williams R. Diabetes and global ageing among 65-99-year-old adults: findings from the International Diabetes Federation Diabetes Atlas, 9 edition. *Diabetes Res Clin Pract*. 2020;162:108078. [doi: [10.1016/j.diabres.2020.108078](https://doi.org/10.1016/j.diabres.2020.108078)] [Medline: [32068097](#)]
5. Liu J, Liu M, Chai Z, Li C, Wang Y, Shen M, et al. Projected rapid growth in diabetes disease burden and economic burden in China: a spatio-temporal study from 2020 to 2030. *Lancet Reg Health West Pac*. 2023;33:100700. [FREE Full text] [doi: [10.1016/j.lanwpc.2023.100700](https://doi.org/10.1016/j.lanwpc.2023.100700)] [Medline: [36817869](#)]
6. Babakhanian M, Razavi A, Rahimi Pordanjani S, Hassanabadi S, Mohammadi G, Fattah A. High incidence of type 1 diabetes, type 2 diabetes and gestational diabetes in Central Iran: a six years results from Semnan health cohort. *Ann Med Surg (Lond)*. 2022;82:104749. [FREE Full text] [doi: [10.1016/j.amsu.2022.104749](https://doi.org/10.1016/j.amsu.2022.104749)] [Medline: [36268322](#)]
7. Baechle C, Stahl-Pehe A, Prinz N, Meissner T, Kamrath C, Holl R, et al. in cooperation with the German Paediatric Surveillance Unit (ESPED), the DPV initiativethe German Center for Diabetes Research (DZD). Prevalence trends of type 1 and type 2 diabetes in children and adolescents in North Rhine-Westphalia, the most populous federal state in Germany, 2002-2020. *Diabetes Res Clin Pract*. 2022;190:109995. [doi: [10.1016/j.diabres.2022.109995](https://doi.org/10.1016/j.diabres.2022.109995)] [Medline: [35853531](#)]
8. Li D, Luo M, Liu Y, Dong J, Geng W, Li X, et al. Increased rates of health management and health education on hypertension and diabetes in Inner Mongolia, China: 10-year population level trends (2009-2018). *Int J Environ Res Public Health*. 2022;19(20). [FREE Full text] [doi: [10.3390/ijerph192013048](https://doi.org/10.3390/ijerph192013048)] [Medline: [36293621](#)]
9. Tomic D, Harding JL, Jenkins AJ, Shaw JE, Magliano DJ. The epidemiology of type 1 diabetes mellitus in older adults. *Nat Rev Endocrinol*. 2025;21(2):92-104. [doi: [10.1038/s41574-024-01046-z](https://doi.org/10.1038/s41574-024-01046-z)] [Medline: [39448829](#)]
10. Han J, Wang H, Liang H-H, Guo J-X. Correlation of the retinopathy degree with the change of ocular surface and corneal nerve in patients with type 2 diabetes mellitus. *Int J Ophthalmol*. 2021;14(5):750-758. [FREE Full text] [doi: [10.18240/ijo.2021.05.17](https://doi.org/10.18240/ijo.2021.05.17)] [Medline: [34012892](#)]
11. Kirthi V, Perumbalath A, Brown E, Nevitt S, Petropoulos IN, Burgess J, et al. Prevalence of peripheral neuropathy in pre-diabetes: a systematic review. *BMJ Open Diabetes Res Care*. 2021;9(1). [FREE Full text] [doi: [10.1136/bmjdrc-2020-002040](https://doi.org/10.1136/bmjdrc-2020-002040)] [Medline: [34006607](#)]
12. Wang L, Peng W, Zhao Z, Zhang M, Shi Z, Song Z, et al. Prevalence and treatment of diabetes in China, 2013-2018. *JAMA*. 2021;326(24):2498-2506. [FREE Full text] [doi: [10.1001/jama.2021.22208](https://doi.org/10.1001/jama.2021.22208)] [Medline: [34962526](#)]
13. Emerging Risk Factors Collaboration. Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation. *Lancet Diabetes Endocrinol*. 2023;11(10):731-742. [FREE Full text] [doi: [10.1016/S2213-8587\(23\)00223-1](https://doi.org/10.1016/S2213-8587(23)00223-1)] [Medline: [37708900](#)]
14. Jyotsna F, Ahmed A, Kumar K, Kaur P, Chaudhary M, Kumar S, et al. Exploring the complex connection between diabetes and cardiovascular disease: analyzing approaches to mitigate cardiovascular risk in patients with diabetes. *Cureus*. 2023;15(8):e43882. [FREE Full text] [doi: [10.7759/cureus.43882](https://doi.org/10.7759/cureus.43882)] [Medline: [37746454](#)]
15. Kumar M, Dev S, Khalid M, Siddenti S, Noman M, John C, et al. The bidirectional link between diabetes and kidney disease: mechanisms and management. *Cureus*. 2023;15(9):e45615. [FREE Full text] [doi: [10.7759/cureus.45615](https://doi.org/10.7759/cureus.45615)] [Medline: [37868469](#)]
16. Kirya M, Bwayo D, Otim M, Mutoo P, Masaba J, Okibure A, et al. Prevalence of biomarkers and associated factors for chronic kidney disease in adult diabetic out-patients in a tertiary hospital in Eastern Uganda - a cross-sectional study. *Res Sq*. 2024. [FREE Full text] [doi: [10.21203/rs.3.rs-3992049/v1](https://doi.org/10.21203/rs.3.rs-3992049/v1)] [Medline: [38496471](#)]
17. Taimur H, Ahmad I, Khan H, Shirayama Y, Okamoto M, Aung MN, et al. A scoping review of type 2 diabetes mellitus in Pakistan investigating the status of glycemic control, awareness, treatment adherence, complications and cost. *Front Endocrinol (Lausanne)*. 2024;15:1441591. [FREE Full text] [doi: [10.3389/fendo.2024.1441591](https://doi.org/10.3389/fendo.2024.1441591)] [Medline: [39649227](#)]
18. Brown MT, Bussell J, Dutta S, Davis K, Strong S, Mathew S. Medication adherence: truth and consequences. *Am J Med Sci*. 2016;351(4):387-399. [doi: [10.1016/j.amjms.2016.01.010](https://doi.org/10.1016/j.amjms.2016.01.010)] [Medline: [27079345](#)]
19. Weinberg Sibony R, Segev O, Dor S, Raz I. Drug therapies for diabetes. *Int J Mol Sci*. Dec 05, 2023;24(24). [doi: [10.3390/ijms242417147](https://doi.org/10.3390/ijms242417147)] [Medline: [38138975](#)]
20. Pallangyo P, Millinga J, Bhalia S, Mkojera Z, Misidai N, Swai HJ, et al. Medication adherence and survival among hospitalized heart failure patients in a tertiary hospital in Tanzania: a prospective cohort study. *BMC Res Notes*. 2020;13(1):89. [FREE Full text] [doi: [10.1186/s13104-020-04959-w](https://doi.org/10.1186/s13104-020-04959-w)] [Medline: [32085803](#)]
21. Zhang, Nie X, Yang X, Mei Q, Xiang X, Cheng L. A meta-analysis of effectiveness of mobile health interventions on health-related outcomes in patients with heart failure. *J Cardiovasc Med (Hagerstown)*. 2024;25(8):587-600. [doi: [10.2459/JCM.0000000000001631](https://doi.org/10.2459/JCM.0000000000001631)] [Medline: [38949146](#)]

22. Rasu RS, Xavier C, Rianon N. Dynamic changes in medication burden leading to fall and hospital readmissions in older adults: toward a strategy for improving risk and managing costs. *J Manag Care Spec Pharm.* 2025;31(1):96-100. [doi: [10.18553/jmcp.2025.31.1.96](https://doi.org/10.18553/jmcp.2025.31.1.96)] [Medline: [39745841](#)]

23. He HM, Cai H, Rong QF, Heng JQ. Investigation of factors influencing medication adherence among elderly patients with chronic diseases and strategies for dealing with them. *Chin Remedies Clin.* 2020;20:1622-1624. [FREE Full text] [doi: [10.11655/zgywylc2020.10.013](https://doi.org/10.11655/zgywylc2020.10.013)]

24. Zhou HB, Zhang YZ, Yang H, Xia Q, Su H. Investigation on medication compliance of elderly patients with type 2 diabetes mellitus. *Diabetes New World.* Feb 16, 2022;25:13-16. [FREE Full text] [doi: [10.16658/j.cnki.1672-4062.2022.04.013](https://doi.org/10.16658/j.cnki.1672-4062.2022.04.013)]

25. Khan II, Pulock OS, Pinky SD, Barua B, Dola TA, Chowdhury P, et al. Treatment noncompliance level among patients with type 2 diabetes mellitus: a hospital based cross-sectional study in Bangladesh. *PLoS One.* 2022;17(9):e0271107. [FREE Full text] [doi: [10.1371/journal.pone.0271107](https://doi.org/10.1371/journal.pone.0271107)] [Medline: [36099268](#)]

26. Zhou JY. Analysis of medication compliance and influencing factors among elderly patients with chronic diseases in Fangshan district, Beijing. *Mod Dis Control Prev.* 2023;34(12):930-957. [FREE Full text] [doi: [10.13515/j.cnki.hnjpm.1006-8414.2023.12.012](https://doi.org/10.13515/j.cnki.hnjpm.1006-8414.2023.12.012)]

27. Zhang JY, Zhang LQ, Tao MX, Chen XL. Analysis of medication adherence status and influencing factors in elderly type 2 diabetes patients. *Pract Prev Med.* 2024;31(1):1382-1385. [FREE Full text] [doi: [10.3969/j.issn.1006-3110.2024.11.025](https://doi.org/10.3969/j.issn.1006-3110.2024.11.025)]

28. Yao YC, Zhong YJ, Yang L. Compliance health education for elderly patients with multidrug use management intervention based on multidisciplinary cooperation. *J Prev Med.* Jan 23, 2023;39(12):1464-1469. [FREE Full text]

29. Li B, Zang S, Ma LP. Health education management in the follow-up of elderly patients with diabetes mellitus. *J Qilu Nurs.* Feb 05, 2023;29(3):111-113. [FREE Full text] [doi: [10.3969/j.issn.1006-7256.2023.03.033](https://doi.org/10.3969/j.issn.1006-7256.2023.03.033)]

30. Poonprapai P, Lerkiatbundit S, Saengcharoen W. Family support-based intervention using a mobile application provided by pharmacists for older adults with diabetes to improve glycaemic control: a randomised controlled trial. *Int J Clin Pharm.* 2022;44(3):680-688. [doi: [10.1007/s11096-022-01389-5](https://doi.org/10.1007/s11096-022-01389-5)] [Medline: [35247147](#)]

31. Mohan A, Majd Z, Johnson ML, Essien EJ, Barner J, Serna O, et al. A motivational interviewing intervention to improve adherence to ACEIs/ARBs among nonadherent older adults with comorbid hypertension and diabetes. *Drugs Aging.* 2023;40(4):377-390. [FREE Full text] [doi: [10.1007/s40266-023-01008-6](https://doi.org/10.1007/s40266-023-01008-6)] [Medline: [36847995](#)]

32. Wang ZM, Sun BY, Hu YY. Influence of remote clinical pharmacy service platform on drug use in older patients with type 2 diabetes mellitus. *Int J Geriatr.* May 20, 2023;44(3):280-283. [FREE Full text] [doi: [10.3969/j.issn.1674-7593.2023.03.005](https://doi.org/10.3969/j.issn.1674-7593.2023.03.005)]

33. Zhang XL, Liu HL, Wang S. Influence of family pharmacists' service on medication adherence and efficacy of elderly patients with type 2 diabetes mellitus in community. *Chin Pharm.* 2024;33(22):48-52. [FREE Full text] [doi: [10.3969/j.issn.1006-4931.2024.22.010](https://doi.org/10.3969/j.issn.1006-4931.2024.22.010)]

34. Lee S, Kim B. Factors affecting nurses' health promotion behavior during the COVID-19 pandemic based on the information-motivation-behavioral skills model. *Medicina (Kaunas).* 2022;58(6). [FREE Full text] [doi: [10.3390/medicina58060720](https://doi.org/10.3390/medicina58060720)] [Medline: [35743983](#)]

35. Park N, Jang S. Effects of mHealth practice patterns on improving metabolic syndrome using the information-motivation-behavioral skills model. *Nutrients.* 2024;16(13). [FREE Full text] [doi: [10.3390/nu16132099](https://doi.org/10.3390/nu16132099)] [Medline: [38999847](#)]

36. Nelson LA, Wallston KA, Kripalani S, LeStourgeon LM, Williamson SE, Mayberry LS. Assessing barriers to diabetes medication adherence using the information-motivation-behavioral skills model. *Diabetes Res Clin Pract.* 2018;142:374-384. [FREE Full text] [doi: [10.1016/j.diabres.2018.05.046](https://doi.org/10.1016/j.diabres.2018.05.046)] [Medline: [29879495](#)]

37. Schoenthaler A, Leon M, Butler M, Steinhaeuser K, Wardzinski W. Development and evaluation of a tailored mobile health intervention to improve medication adherence in black patients with uncontrolled hypertension and type 2 diabetes: pilot randomized feasibility trial. *JMIR Mhealth Uhealth.* 2020;8(9):e17135. [FREE Full text] [doi: [10.2196/17135](https://doi.org/10.2196/17135)] [Medline: [32965230](#)]

38. Xu Q, Wu P, Du J, Zhuang W, He X, Ma Y, et al. Online short videos promoting public breast cancer literacy: a pretest-posttest control group trial on efficiency, attitude, and influencing factors. *Front Public Health.* 2023;11:1198780. [FREE Full text] [doi: [10.3389/fpubh.2023.1198780](https://doi.org/10.3389/fpubh.2023.1198780)] [Medline: [37397762](#)]

39. Liang H, Pang H. The cognitive, behavioral and interpersonal impacts of virtual practice with short health videos on Chinese ageing women: a discursive approach. *Int J Environ Res Public Health.* 2022;19(12). [FREE Full text] [doi: [10.3390/ijerph19127173](https://doi.org/10.3390/ijerph19127173)] [Medline: [35742422](#)]

40. Gould CE, Carlson C, Wetherell JL, Goldstein MK, Anker L, Beaudreau SA. Brief video-delivered intervention to reduce anxiety and improve functioning in older veterans: pilot randomized controlled trial. *JMIR Aging.* 2024;7:e56959. [FREE Full text] [doi: [10.2196/56959](https://doi.org/10.2196/56959)] [Medline: [39652863](#)]

41. Al-Kharouf MS, Abdeljalil MH, Obeidat NM, Oweidat KA, Awwad O. Video-based teach-to-goal intervention on inhaler technique on adults with asthma and COPD: a randomized controlled trial. *PLoS One.* 2023;18(6):e0286870. [FREE Full text] [doi: [10.1371/journal.pone.0286870](https://doi.org/10.1371/journal.pone.0286870)] [Medline: [37294823](#)]

42. Wang M, Lim PY, Lee K, Sowtali SN, Jiang Q, Thew HZ. Effectiveness of diabetes little helper video intervention on medication adherence among elderly patients with type 2 diabetes mellitus in Henan, China: study protocol for a randomised

controlled trial. *BMJ Open*. 2025;15(4):e093191. [[FREE Full text](#)] [doi: [10.1136/bmjopen-2024-093191](https://doi.org/10.1136/bmjopen-2024-093191)] [Medline: [40258641](#)]

43. Chinese Elderly Type 2 Diabetes PreventionTreatment of Clinical Guidelines Writing Group. [Clinical guidelines for prevention and treatment of type 2 diabetes mellitus in the elderly in China (2022 edition)]. *Zhonghua Nei Ke Za Zhi*. Jan 01, 2022;61(1):12-50. [doi: [10.3760/cma.j.cn112138-20211027-00751](https://doi.org/10.3760/cma.j.cn112138-20211027-00751)] [Medline: [34979769](#)]

44. Lemeshow S, Hosmer DW. Adequacy of Sample Size in Health Studies. New Jersey. Wiley & Sons; 1992:120.

45. Cao Z. Analysis of the impact of clinical pharmacist guidance on rational medication and compliance in elderly patients with chronic diseases. *Chin J Mod Drug Appl*. 2024;18(6):160-163. [[FREE Full text](#)] [doi: [10.14164/j.cnki.cn11-5581/r.2024.06.042](https://doi.org/10.14164/j.cnki.cn11-5581/r.2024.06.042)]

46. Wu X, Qian J, Gong L. Targeted nursing interventions based on SEAMS assessment: effects on blood pressure control and medication adherence in elderly patients with hypertension. *Heilongjiang Med Pharm*. Apr 8, 2024;47(2):84-89. [[FREE Full text](#)] [doi: [10.3969/j.issn.1008-0104.2024.02.026](https://doi.org/10.3969/j.issn.1008-0104.2024.02.026)]

47. Yan C, Ding Y. Micro-lecture design and development based on Wondershare Animiz. *Shoes Technol Des*. Jul 28, 2025:5-29. [[FREE Full text](#)] [doi: [10.31958/je.v3i1.10120](https://doi.org/10.31958/je.v3i1.10120)]

48. Sowtali SN. Development, implementation and evaluation of family-based educational program on nutrient intake and stroke knowledge for first ever stroke patients. In: Universiti Sains Malaysia. Malaysia. Universiti Sains Malaysia; 2016.

49. Dong X-F, Liu Y-J, Wang A, Lv P-H. Psychometric properties of the Chinese version of the self-efficacy for appropriate medication use scale in patients with stroke. *Patient Prefer Adherence*. 2016;10:321-327. [[FREE Full text](#)] [doi: [10.2147/PPA.S101844](https://doi.org/10.2147/PPA.S101844)] [Medline: [27042023](#)]

50. Dong XF, Liu YJ, Wang AX. Reliability and validity of the Chinese version self-efficacy for appropriate medication use scale. *J Nurs Sci*. 2015;30:47-49. [doi: [10.3870/hlxzz.2015.11.047](https://doi.org/10.3870/hlxzz.2015.11.047)]

51. Xiang G-P. A study on the effect of health education on knowledge, attitude, behavior of safe medication for community-dwelling elderly with chronic diseases. In: Central South University. Changsha. Central South University; Nov 2012:1-55.

52. Tang J, Gao LL, Hu XL, Wu JP, Yu KH, Liu SH. The reliability and validity of the Chinese version of beliefs about medicines questionnaire-specific among patients with type 2 diabetes mellitus. *J Nurs Sci*. 2019;34:25-28. [[FREE Full text](#)]

53. Huang SF, Chen LX, Ye YM, Gong GM, Shi GF. Preparation of empty nester social support scale and analysis of its reliability and validity. *Nurs Res*. Mar 09, 2017;31(1):537-539. [[FREE Full text](#)] [doi: [10.3969/j.issn.1009-6493.2017.05.007](https://doi.org/10.3969/j.issn.1009-6493.2017.05.007)]

54. Yang C, Lee DTF, Chair SY. Validation and adaption of an information-motivation-behavioral skills model of medication adherence in older patients with multimorbidity. *Patient Educ Couns*. 2023;113:107756. [doi: [10.1016/j.pec.2023.107756](https://doi.org/10.1016/j.pec.2023.107756)] [Medline: [37156122](#)]

55. Oh E, Kim C, Schlenk EA. A predictive model for medication adherence in older adults with heart failure. *Eur J Cardiovasc Nurs*. Oct 05, 2024;23(6):635-643. [doi: [10.1093/eurjcn/zvae021](https://doi.org/10.1093/eurjcn/zvae021)] [Medline: [38408016](#)]

56. Mirzaei-Alavijeh M, Yarmoradi S, Khashij S, Jalilian F. Application of the information-motivation-behavioral skills model to improve medication adherence among older adults with type 2 diabetes: findings from a quasi-experimental study in Kermanshah, Iran. *BMC Geriatr*. May 13, 2025;25(1):328. [[FREE Full text](#)] [doi: [10.1186/s12877-025-06000-w](https://doi.org/10.1186/s12877-025-06000-w)] [Medline: [40361006](#)]

57. Yang C, Lee DTF, Wang X, Chair SY. Effects of a nurse-led medication self-management intervention on medication adherence and health outcomes in older people with multimorbidity: a randomised controlled trial. *Int J Nurs Stud*. 2022;134:104314. [doi: [10.1016/j.ijnurstu.2022.104314](https://doi.org/10.1016/j.ijnurstu.2022.104314)] [Medline: [35849886](#)]

58. Xiong YY, Wan J. The influence of WeChat platform technology for the rational drug use and drug compliance of elderly hypertensive patients in the community. *Shanghai Med Pharm J*. Aug 25, 2023;44(16):36-39. [[FREE Full text](#)] [doi: [10.3969/j.issn.1006-1533.2023.16.011](https://doi.org/10.3969/j.issn.1006-1533.2023.16.011)]

59. Praveen CK, Srinivasan K. Psychological impact and influence of animation on viewer's visual attention and cognition: a systematic literature review, open challenges, and future research directions. *Comput Math Methods Med*. 2022;2022:8802542. [[FREE Full text](#)] [doi: [10.1155/2022/8802542](https://doi.org/10.1155/2022/8802542)] [Medline: [36092789](#)]

60. Chen J, Wei C, Deng L. Study on the influence of multi-faceted health education intervention in hospital-community-family model on the knowledg-attitude-practice of safe and rational drug use in elderly chronic co-patients. *Chin J Hosp Pharm*. May 17, 2020;40(4):452-455. [[FREE Full text](#)] [doi: [10.13286/j.1001-5213.2020.04.19](https://doi.org/10.13286/j.1001-5213.2020.04.19)]

61. Zhou J. The impact of pharmaceutical care management on the rationality of medication use in elderly patients with multiple coexisting diseases. *J North Pharm*. Jul 1, 2023;20(7):113-115. [[FREE Full text](#)] [doi: [10.3969/j.issn.1672-8351.2023.07.038](https://doi.org/10.3969/j.issn.1672-8351.2023.07.038)]

62. Wang HH, Wang LY, Hou WY, Zhao YS. Effects of Motivational Interview on Medication Compliance?Self-management and Blood Glucose Control in Elderly Patieuts with Type 2 Diabetes. *Henan Medical Research*. Mar 31, 2022;31(6):1023-1027. [[FREE Full text](#)] [doi: [10.3969/j.issn.1004-437X.2022.06.015](https://doi.org/10.3969/j.issn.1004-437X.2022.06.015)]

63. Wan X, Cheng X, Wang Y, Li Y. Study on the influence of personalised health education on health behaviour, knowledge, attitude and practice of medication in elderly patients with chronic disease. *Chin J Health Educ*. Apr 25, 2022;37(12):1135-1138. [[FREE Full text](#)] [doi: [10.16168/j.cnki.issn.1002-9982.2021.12.016](https://doi.org/10.16168/j.cnki.issn.1002-9982.2021.12.016)]

64. Yang YX, Fang XX, Zhang HM, Wang H, Zhang CF, Wang ZP, et al. Effect of life retrospective intervention on belief about medication and perceived happiness in elderly patients with chronic kidney disease. *Chin J Mod Nurs.* Jul 25, 2019;25(6):685-688. [FREE Full text] [doi: [10.3760/cma.j.issn.1674-2907.2019.06.006](https://doi.org/10.3760/cma.j.issn.1674-2907.2019.06.006)]
65. Li LS, Tang Q, Wang C, Wu WH, Wu HY, Gao ZQ, et al. The influence of rational drug use management mode of the elderly in community on patients' knowledge, attitude and practice of drug use. *Chin Gen Pract.* Sep 5, 2024;27(25):3129-3135. [FREE Full text] [doi: [10.12114/j.issn.1007-9572.2023.0798](https://doi.org/10.12114/j.issn.1007-9572.2023.0798)]
66. Czaja S, Boot W, Charness N, Rogers W, Sharit J. Improving social support for older adults through technology: findings from the PRISM randomized controlled trial. *Gerontologist.* 2018;58(3):467-477. [FREE Full text] [doi: [10.1093/geront/gnw249](https://doi.org/10.1093/geront/gnw249)] [Medline: [28201730](https://pubmed.ncbi.nlm.nih.gov/28201730/)]
67. Hu L, Zhang XF, Song ZZ, Wang KJ, Song J, Jia YC, et al. The impact of family collaborative health education on the cancer-related fatigue, psychological resilience, and self-efficacy of elderly lung cancer patients. *Chin J Gerontol.* Jun 25, 2023;3047-3050. [FREE Full text] [doi: [10.3969/j.issn.1005-9202.2023.12.059](https://doi.org/10.3969/j.issn.1005-9202.2023.12.059)]
68. Gong YX, Li Y, Chen XL, Shang Y, Feng QQ. Effects of WeChat carrier information-knowledge-attitude-practice collaborative nursing intervention on health literacy and social support in elderly patients with chronic heart failure. *Chin Evidence-Based Nurs.* Jan 22, 2025;11(2):277-280. [FREE Full text] [doi: [10.12102/j.issn.2095-8668.2025.02.016](https://doi.org/10.12102/j.issn.2095-8668.2025.02.016)]

Abbreviations

CG: control group

CONSORT: Consolidated Standards of Reporting Trials

DM: diabetes mellitus

I-CVI: Item-level Content Validity Index

IG: intervention group

IMB: information-motivation-behavioral skills

LOCF: last observation carried forward

RCT: randomized controlled trial

S-CVI: Scale-level Content Validity Index

T2DM: type 2 diabetes mellitus

Edited by N Cahill; submitted 08.Jun.2025; peer-reviewed by Z-R Fan, H Almomani, AN Ali; comments to author 20.Oct.2025; revised version received 28.Nov.2025; accepted 11.Dec.2025; published 17.Feb.2026

Please cite as:

Wang M, Lee K, Thew HZ, Sowtali SN, Jiang Q, Zhao Z, Liu Y, Lim PY

Effectiveness of the Mobile-Based Diabetes Little Helper Video Intervention on Medication Adherence Among Older Adults Living With Type 2 Diabetes Mellitus, Henan, China: Randomized Controlled Trial

J Med Internet Res 2026;28:e78731

URL: <https://www.jmir.org/2026/1/e78731>

doi: [10.2196/78731](https://doi.org/10.2196/78731)

PMID:

©Meng Wang, Khuan Lee, Hui Zhu Thew, Siti Noorkhairina Sowtali, Qiuhan Jiang, Zhengyan Zhao, Yu Liu, Poh Ying Lim. Originally published in the Journal of Medical Internet Research (<https://www.jmir.org>), 17.Feb.2026. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research (ISSN 1438-8871), is properly cited. The complete bibliographic information, a link to the original publication on <https://www.jmir.org/>, as well as this copyright and license information must be included.